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Endometriosis and risk of ovarian cancer
ABSTRACT
Endometriosis is common in premenopausal women and affects about 10% of women of reproductive age. It 
is a benign condition but demonstrates malignant behaviour with recurrences and metastases. Its tendency to 
increase the risk of specific subtypes of ovarian cancer is being discussed, because they exhibit specific clinical 
features that distinguish them from classical ovarian cancer. Malignant transformation of endometriosis goes 
through its transition to atypical endometriosis. Although endometriosis-associated ovarian carcinomas have 
a good prognosis, adequate follow-up and monitoring after treatment of endometriosis are recommended.
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Endometriosis (E) is one of the most common dis-
eases in premenopausal women, affecting about 10% of 
women of reproductive age [1]. It is a chronic disease 
characterized by endometrium-like tissue, glands, and 
stroma outside the uterine cavity. It is oestrogen-depend-
ent and most commonly affects the ovaries, fallopian 
tubes, and the pelvic peritoneum. The disease often has 
a substantial impact on the quality of life of those affected. 
Usually, it manifests itself with the following symptoms: 
dysmenorrhea, dyspareunia, chronic pelvic pain, infertil-
ity, urinary or digestive symptoms [2]. The diagnosis can 
be suspected by ultrasound and MRI tests, but the final 
diagnosis is based on histopathological examination [3]. 
Various theories explain the occurrence of endometriosis, 
the most common being retrograde menstruation, genetic 
predisposition, lymphatic spread, immune dysfunction, 
metaplasia, or environmental causes [4, 5]. Although E is 
considered a benign disease, it increases the risk of ovar-
ian cancer [6–9]. Two main mechanisms are suggested to 
explain this correlation: (1) both diseases coexist and are 
the result of shared risk factors and their effects; (2) en-
dometriotic cells gradually transform into cancer cells [1].
Atypical E is considered an intermediate state between 
E and OC [10]. This leads to the conclusion that E is a pre-
cancerous condition. More than 2/3 of endometriosis-relat-
ed ovarian tumours develop in the presence of atypical E 
[11]. Some of the risk factors for the development of atypical 
E are: early age of onset, long duration of disease, obesity, 
dysmenorrhea, perimenopause and menopause, irregular 
vaginal bleeding, a gynaecological examination of tumour 
fixation, tumour diameter over 80 mm, a rapid increase 
in tumour size, the number of abortions, uterine myoma, 
thyroid disease, and multiple foci of endometriosis [12].
Endometriosis and OC share some quite similar 
features such as local invasion, neoangiogenesis, 
increased expression of vascular endothelial growth 
factor (VEGF), lymphangiogenesis, resistance to the 
mechanisms of apoptosis, COX-2 overexpression, and 
genomic instability.
To determine whether endometriosis is associated 
with an increased risk of ovarian cancer, 13 extensive 
epidemiological studies were conducted in North 
America, Australia, and Europe on 23,000 women 
(13,326 controls; 7,911 with invasive ovarian carcinoma 
(OC), and 1,907 with borderline malignancies). The 
studies established the following results [13]. Women 
with a history of endometriosis have a significantly 
higher risk (> 2.5 times) of developing three specific 
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histotypes of ovarian carcinoma: clear cell carcinoma 
(atypical endometriosis is the immediate precursor of 
clear cell carcinoma) [14]; endometrioid carcinoma; 
low-grade serous carcinoma (LGSCO). Several studies 
published between 2008 and 2014 validate the term 
endometriosis-associated ovarian carcinomas (EAOC) 
[15–19]. EAOC is presented as an ovarian carcinoma 
with both cancer cells and endometriotic cells observed 
in the same ovary, cancer presence in one ovary, and 
endometriosis in the other ovary; or presence of ovarian 
cancer and pelvic endometriosis [20].
The most important conclusions reached by the 
authors of these studies are the following:
1. Ovarian endometriosis is a risk factor that can lead 
to the development of endometrioid and clear cell 
ovarian carcinomas within 5 years [15].
2. The risk of malignant transformation varies between 
2 and 17% according to a meta-analysis [16].
3. Risk factors for EAOC are: ovarian endometrio-
ma ≥ 9 cm, and peri- and post-menopausal patients 
[17].
4. EAOC patients are 10 years younger (mean age 
50 years) than other ovarian cancer patients [18].
5. Hyperoestrogenemia is a risk factor for the develop-
ment of EAOC [19].
EAOC is presented with some specific clinical 
features that distinguish it from OC: it affects younger 
patients, shows lower CA-125 levels, it has a better 
prognosis and a higher number of clear cells than in 
ovarian cancer [21]. 
The relative risk (RR) of developing specific histo-
logical subtypes of OC for patients with endometriosis 
is calculated as follows [16]:
1. clear cell ovarian carcinoma — 3.05;
2. endometrioid ovarian carcinoma — 2.04;
3. low-grade serous ovarian carcinoma — 2.11;
4. high-grade serous ovarian carcinoma — 1.13;
5. mucinous ovarian carcinoma — 1.02.
The most extensive and significant survey reported 
on this topic is a meta-analysis by Kim et al. (2014) 
[22], which included 1,625 studies and a contingent of 
444,255 patients. The authors compare the EAOC with 
the non-EAOC and reach the following conclusions:
1. endometriosis increases the risk of OC (RR 1.265).
2. EAOC patients have better prognosis and survival.
3. EAOCs are more common in nulliparous women 
and are usually in FIGO stage I, II.
4. endometrioid (RR = 1.759) and clear cell (RR 
= 2.606) histological subtypes are more common in 
EAOC, while serous carcinomas are less frequent 
(RR = 0.733).
Specific histological, cellular, and molecular markers 
have been identified as responsible for the malignant 
transformation of E and underlie the pathogenesis of 
EAOC [22]. These are: 
1. KRAS and PTEN genes mutations;
2. ARID1A gene mutation — it occurs in 46% of the 
cases of clear cell ovarian carcinoma (CCOC), and 
in only 30% of endometrioid ovarian carcinoma 
(EOC) cases; it is not found in high-grade serous 
ovarian carcinoma (HGSOC).
These mutations inhibit the expression of the 
BAF250a protein (a tumour-suppressor gene). They 
are regarded as markers of malignant transformation 
underlying the pathogenesis of the EAOC. 
There are several stages of malignant transforma-
tion: normal endometrium, endometriosis, atypical 
endometriosis, EAOC. External and internal factors, 
inflammation, and oxidative stress contribute to the 
progression from one stage to the next. However, genetic 
factors and mutations in the genes mentioned above 
exert the most significant influence. It is assumed that 
the immune system (macrophages) and endometrioid 
cells’ proliferative activity have an additional role as 
co-factors [23].
Apart from the indisputable evidence of endome-
triosis association with ovarian carcinoma, other factors 
are reducing the risk of ovarian cancer in women with 
endometriosis. Since 2004, oral contraceptives have been 
shown to reduce the risk of OC by 50–60% in women 
with endometriosis [24]. Studies published in 2013 estab-
lished that unilateral oophorectomy significantly reduces 
the risk of OC compared to endometriosis patients who 
underwent conservative nonsurgical treatment. Ad-
ditionally, the studies reported on the protective effect 
of childbirth and hysterectomy [25, 26].
The available data considered so far indisputably 
prove that endometriosis is associated with the devel-
opment of some OC histological types. An intriguing 
question is whether there is a link between the loca-
tion of E and the risk of cancer. The results of Finn-
ish study (data retrieved from the Finnish Hospital 
Discharge Registry and the Finnish Cancer Registry) 
were published in 2018 [26]. The study covered the 
period of 1987 to 2012, and included 49,933 women 
with surgically verified endometriosis. Depending on 
the organ localization of endometriosis, the distribu-
tion is as follows: ovaries — 23,210 cases; peritoneum 
— 20,187 cases; deep infiltrating endometriosis (DIE) 
— 2,372 cases.
The Finnish study shows that patients with endo-
metriosis have a 2.3 times higher risk of developing OC 
— EAOC are endometrioid and clear cell histological 
subtypes. In addition to these confirmatory results, 
the authors make an original contribution by proving 
that endometriosis patients have a significant risk of 
developing borderline ovarian tumours (BOT) [27]. 
Depending on the localization of endometriosis, ovarian 
cancer risk is highest among women with ovarian endo-
metriosis; peritoneal and DIE do not increase the risk.
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After a 10-year follow-up, the authors found that 
the excess risk of ovarian cancer among women with 
ovarian endometriosis translates into two excess cases 
per 1,000 patients.
In conclusion, the following clinical groups are 
at an increased risk of developing EAOC: patients 
aged > 45 years; nulliparous patients; diagnosis of 
endometriosis in postmenopausal women; endometrio-
mas ≥ 9 cm; hyperoestrogenism.
The frequency of EAOC varies between 2 and 17%, 
and endometrioid and clear cell ovarian carcinomas are 
the most common. Only ovarian endometriosis (not 
peritoneal and deep infiltrating endometriosis) is related 
to the progression of EAOC. Malignant transformation 
progresses to atypical endometriosis and is most often 
due to mutations in several genes. Although EAOC has 
a good prognosis, adequate follow-up and monitoring 
after treatment of endometriosis are recommended.
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